Drug Profile
AM 201
Alternative Names: AM-201Latest Information Update: 01 Nov 2023
Price :
$50
*
At a glance
- Originator AbClon
- Class Antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rheumatoid arthritis
- Discontinued Psoriasis
Most Recent Events
- 01 Nov 2023 Discontinued - Preclinical for Psoriasis in South Korea (unspecified route)
- 04 Sep 2023 Preclinical development is ongoing for Rheumatoid arthritis in South Korea (AbClon pipeline, September 2023)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Psoriasis in South Korea